View:
Download DOC
Download PDF
Download XLS

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2021

 

Commission File Number: 001-34541

 

GLOBAL CORD BLOOD CORPORATION
(Translation of registrant’s name into English)

 

48th Floor, Bank of China Tower
1 Garden Road
Central
            Hong Kong S.A.R.            
(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x            Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or Global Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to conform these statements to actual results, unless required by law.

 

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the ongoing impact of 2019 novel coronavirus (“COVID-19”), including the partial lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC (including but not limited to cord blood license related regulations, Biosecurity laws, antitrust laws) and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments affecting U.S. listed issuers whose independent registered public accounting firms are based in the PRC and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions; the non-binding proposal letter from Alternate Ocean Investment Company Limited and the potential transaction contemplated by such letter, and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 

 

 

 

Results of Operations and Financial Condition

 

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2021 of the Company.

 

 

 

 

GLOBAL CORD BLOOD CORPORATION 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS 

As of March 31 and September 30, 2021

 

   March 31,  September 30, 
   2021  2021 
   RMB  RMB  US$ 
   (in thousands except share data) 
ASSETS             
Current assets             
Cash and cash equivalents   6,075,798   6,390,632   991,812 
Accounts receivable, less allowance for credit losses (March 31, 2021: RMB137,961; September 30, 2021: RMB150,060 (US$23,289))   130,298   144,667   22,452 
Inventories   44,257   33,821   5,250 
Prepaid expenses and other receivables   47,788   79,343   12,313 
Total current assets   6,298,141   6,648,463   1,031,827 
Property, plant and equipment, net   498,656   484,434   75,183 
Operating lease right-of-use assets   5,039   3,969   616 
Non-current deposits   344,752   343,529   53,315 
Non-current accounts receivable, less allowance for credit losses (March 31, 2021: RMB67,095; September 30, 2021: RMB62,544 (US$9,707))   217,208   241,377   37,461 
Inventories   91,446   93,261   14,474 
Intangible assets, net   88,202   85,892   13,330 
Investment in equity securities at fair value   117,911   108,974   16,912 
Other equity investment   189,129   189,129   29,352 
Deferred tax assets   55,845   59,230   9,192 
Total assets   7,906,329   8,258,258   1,281,662 
              
LIABILITIES             
Current liabilities             
Accounts payable   9,479   13,442   2,086 
Accrued expenses and other payables   136,448   153,872   23,880 
Operating lease liabilities   1,636   1,675   260 
Deferred revenue   449,359   451,022   69,998 
Income tax payable   29,547   30,767   4,775 
Total current liabilities   626,469   650,778   100,999 
Non-current deferred revenue   2,392,906   2,441,499   378,915 
Non-current operating lease liabilities   147   50   8 
Other non-current liabilities   482,224   495,826   76,951 
Deferred tax liabilities   16,132   16,701   2,592 
Total liabilities   3,517,878   3,604,854   559,465 
              
EQUITY             
Shareholders’ equity of Global Cord Blood Corporation             
Ordinary shares             
-US$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and September 30, 2021, respectively   83   83   13 
Additional paid-in capital   2,101,582   2,101,582   326,161 
Treasury stock, at cost (March 31 and September 30, 2021: 136,899 shares, respectively)   (2,815)  (2,815)  (437)
Accumulated other comprehensive losses   (103,179)  (105,354)  (16,351)
Retained earnings   2,386,187   2,648,344   411,016 
Total equity attributable to Global Cord Blood Corporation   4,381,858   4,641,840   720,402 
Non-controlling interests   6,593   11,564   1,795 
Total equity   4,388,451   4,653,404   722,197 
Total liabilities and equity   7,906,329   8,258,258   1,281,662 

 

 

 

 

GLOBAL CORD BLOOD CORPORATION 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 

For the Three Months and Six Months Ended September 30, 2020 and 2021

 

   Three months ended September 30,  Six months ended September 30, 
   2020  2021  2020  2021 
   RMB  RMB  US$  RMB  RMB  US$ 
   (in thousands except per share data) 
Revenues   285,607   313,670   48,681   566,520   628,844   97,595 
Cost of revenues   (44,698)  (46,209)  (7,172)  (88,161)  (94,050)  (14,596)
Gross profit   240,909   267,461   41,509   478,359   534,794   82,999 
Operating expenses                         
Research and development   (4,953)  (5,573)  (865)  (9,298)  (10,671)  (1,656)
Sales and marketing   (54,124)  (56,924)  (8,834)  (109,184)  (116,327)  (18,054)
General and administrative   (42,671)  (44,512)  (6,908)  (87,207)  (90,788)  (14,090)
Total operating expenses   (101,748)  (107,009)  (16,607)  (205,689)  (217,786)  (33,800)
Operating income   139,161   160,452   24,902   272,670   317,008   49,199 
Other income/(expenses), net                         
Interest income   8,810   7,989   1,240   15,577   16,179   2,511 
Foreign currency exchange gains/(losses)   66   (15)  (2)  108   131   20 
Change in fair value of equity securities   5,699   (12,616)  (1,958)  24,104   (7,015)  (1,089)
Dividend income   1,281   —   —   1,281   1,120   174 
Others   1,195   583   90   2,918   1,222   190 
Total other income/(expenses), net   17,051   (4,059)  (630)  43,988   11,637   1,806 
Income before income tax   156,212   156,393   24,272   316,658   328,645   51,005 
Income tax expense   (22,890)  (28,251)  (4,384)  (48,911)  (61,517)  (9,547)
Net income   133,322   128,142   19,888   267,747   267,128   41,458 
Net income attributable to non-controlling interests   (1,888)  (2,406)  (373)  (3,804)  (4,971)  (772)
Net income attributable to Global Cord Blood Corporation’s shareholders   131,434   125,736   19,515   263,943   262,157   40,686 
                          
Earnings per share:                         
Attributable to ordinary shares                         
- Basic   1.08   1.03   0.16   2.17   2.15   0.33 
- Diluted   1.08   1.03   0.16   2.17   2.15   0.33 
Other comprehensive losses, net of nil income taxes                   
-Foreign currency translation adjustments   (4,202)  (229)  (36)  (4,641)  (2,175)  (338)
Comprehensive income   129,120   127,913   19,852   263,106   264,953   41,120 
                          
Comprehensive income attributable to non-controlling interests   (1,888)  (2,406)  (373)  (3,804)  (4,971)  (772)
Comprehensive income attributable to Global Cord Blood Corporation’s shareholders   127,232   125,507   19,479   259,302   259,982   40,348 

 

 

 

 

Other Events

 

On November 24, 2021, the Company issued a press release announcing unaudited condensed consolidated financial results for the three months and six months ended September 30, 2021. A copy of the press release is attached as Exhibit 99.1.

 

Exhibits  
   
Exhibit No. Description
   
99.1 Press Release dated November 24, 2021

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GLOBAL CORD BLOOD CORPORATION
   
  By: /s/ Albert Chen
  Name: Albert Chen
  Title: Chief Financial Officer
   
Dated: November 24, 2021  

 

 

 

 

Exhibit 99.1

 

 

 

Global Cord Blood Corporation Reports Financial Results 

for the Second Quarter and First Half of Fiscal 2022

 

Added 19,066 New Subscribers in 2Q22 

Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million) 

Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million) 

Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million) 

Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Million) 

Conference Call to be Held on November 26, 2021, at 8:00 a.m. ET

 

HONG KONG, China, November 24, 2021 -- Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended September 30, 2021.

 

Second Quarter of Fiscal 2022 Highlights

 

  · Revenues increased by 9.8% year-over-year (“YoY”) to RMB313.7 million ($48.7 million).

  · New subscribers and accumulated subscriber base were 19,066 and 938,0921, respectively.

  · Gross profit increased by 11.0% YoY to RMB267.5 million ($41.5 million). Gross margin increased to 85.3% from 84.3% in the prior year period.

  · Operating income increased by 15.3% YoY to RMB160.5 million ($24.9 million). Operating margin increased to 51.2% from 48.7% in the prior year period.
  · Operating income before depreciation and amortization (“non-GAAP operating income2”) increased by 14.1% YoY to RMB172.8 million ($26.8 million).

  · Net income attributable to the Company’s shareholders decreased by 4.3% YoY to RMB125.7 million ($19.5 million), mainly due to the decrease in fair value of equity securities (“mark-to-market loss”) and the absence of dividend income.

  · Net cash provided by operating activities was RMB157.0 million ($24.4 million).

 

First Half of Fiscal 2022 Highlights

 

  · Revenues increased by 11.0% YoY to RMB628.8 million ($97.6 million).

  · New subscribers and accumulated subscriber base were 38,739 and 938,0921, respectively.

  · Gross profit increased by 11.8% YoY to RMB534.8 million ($83.0 million).

  · Operating income increased by 16.3% YoY to RMB317.0 million ($49.2 million).
  · Non-GAAP operating income2 increased by 14.8% YoY to RMB341.3 million ($53.0 million).

  · Net income attributable to the Company’s shareholders decreased by 0.7% to RMB262.2 million ($40.7 million), mainly due to mark-to-market loss of equity securities.

  · Net cash provided by operating activities was RMB329.8 million ($51.2 million).

 

“Despite the uncertainty of industry-related regulation, long-standing challenges of China’s population structure, and lingering effects from the COVID-19 pandemic, we managed to recruit 19,066 new subscribers in the second quarter of fiscal 2022, in line with management’s expectations,” said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. “As we continue to monitor relevant regulations and carry on with our organic growth efforts, we have directed ample resources to analyze business development opportunities in-depth to foster the long-term growth of the Company.”

 

 

 

 

Summary – Second Quarter and First Half Ended September 30, 2020 and 2021

 

   Three Months Ended September 30,   Six Months Ended September 30, 
   2020   2021   2020   2021 
(in thousands)  RMB   RMB   US$   RMB   RMB   US$ 
Revenues   285,607    313,670    48,681    566,520    628,844    97,595 
Gross Profit   240,909    267,461    41,509    478,359    534,794    82,999 
Operating Income3   139,161    160,452    24,902    272,670    317,008    49,199 
Change in Fair Value of Equity Securities   5,699    (12,616)   (1,958)   24,104    (7,015)   (1,089)
Dividend Income   1,281    -    -    1,281    1,120    174 
Net Income Attributable to the Company’s Shareholders   131,434    125,736    19,515    263,943    262,157    40,686 

Earnings per Ordinary Share (RMB/US$)

                              
  – Basic   1.08    1.03    0.16    2.17    2.15    0.33 
  – Diluted   1.08    1.03    0.16    2.17    2.15    0.33 
                               
Revenues Breakdown (%)                              
Processing Fees and Other Services   57.5%   57.5%        57.5%   58.0%     
Storage Fees   42.5%   42.5%        42.5%   42.0%     
                               
New Subscribers (persons)   17,643    19,066         34,876    38,739      
Total Accumulated Subscribers (persons)   867,180    938,0921        867,180    938,0921     

 

Summary – Selected Cash Flow Statement Items

 

   Three Months Ended September 30,   Six Months Ended September 30, 
   2020   2021   2020   2021 
(in thousands)  RMB   RMB   US$   RMB   RMB   US$ 
Net cash provided by operating activities   174,814    156,976    24,364    274,643    329,799    51,186 
Net cash used in investing activities   (3,876)   (3,687)   (572)   (11,320)   (6,233)   (967)
Net cash used in financing activities   (6,074)   -    -    (6,074)   (7,729)   (1,200)

 

Second Quarter of Fiscal 2022 Financial Results

 

REVENUES. Revenues increased by 9.8% YoY to RMB313.7 million ($48.7 million) in the second quarter of fiscal 2022, as a result of the increase in processing fees from new subscribers and growth in storage fee revenues.

 

The Company recruited 19,066 new subscribers during the reporting quarter, an increase of 8.1% YoY, partially due to the lower subscriber base in the prior year period. Revenues generated from processing fees and other services increased by 9.7% YoY to RMB180.3 million ($28.0 million), representing 57.5% of total revenues, same as in the prior year period.

 

The accumulated subscriber base as of September 30, 2021 expanded to 938,0921. Revenues generated from storage fees in the reporting quarter increased by 10.0% YoY to RMB133.4 million ($20.7 million).

 

GROSS PROFIT. Gross profit for the second quarter increased by 11.0% YoY to RMB267.5 million ($41.5 million) and gross margin increased to 85.3% from 84.3% in the prior year period as efficiency gain outpaced rising labor cost.

 

 

 

 

OPERATING INCOME. Topline improvement and postponing various sales and marketing activities lifted operating income. Operating income for the second quarter increased by 15.3% YoY to RMB160.5 million ($24.9 million). Operating margin improved to 51.2% from 48.7% in the prior year period. Depreciation and amortization expenses were RMB12.4 million ($1.9 million), compared to RMB12.3 million in the prior year period. Non-GAAP operating income2 increased by 14.1% YoY to RMB172.8 million ($26.8 million).

 

Research and Development Expenses. Research and development expenses increased to RMB5.6 million ($0.9 million) from RMB5.0 million in the prior year period.

 

Sales and Marketing Expenses. Sales and marketing expenses increased by 5.2% YoY to RMB56.9 million ($8.8 million), as staff related expenses grew while the Company continued to hold back some marketing and promotional activities. Sales and marketing expenses as a percentage of revenues decreased to 18.1% from 19.0% in the prior year period and 18.8% in the prior quarter.

 

General and Administrative Expenses. General and administrative expenses amounted to RMB44.5 million ($6.9 million) compared to RMB42.7 million in the prior year period. The increase was led by higher staff costs. General and administrative expenses as a percentage of revenues decreased to 14.2% from 14.9% in the prior year period.

 

OTHER INCOME AND EXPENSES. In the reporting period, the Company recognized a mark-to-market loss of RMB12.6 million ($2.0 million), compared to a mark-to-market gain of RMB5.7 million in the prior year period. The changes were attributable to the Company’s investments in equity securities. In addition, no dividend was recorded in the reporting quarter, whereas RMB1.3 million dividend was recorded in the prior year period.

 

NET INCOME ATTRIBUTABLE TO THE COMPANY’S SHAREHOLDERS. As the increase in operating income offset by the mark-to-market loss of equity securities, income before income tax for the reporting quarter slightly increased by 0.1% YoY to RMB156.4 million ($24.3 million). Income tax expense was RMB28.3 million ($4.4 million). Net income attributable to the Company’s shareholders decreased by 4.3% YoY to RMB125.7 million ($19.5 million). Net margin for the second quarter was 40.1%.

 

EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the second quarter of fiscal 2022 was RMB1.03 ($0.16).

 

First Half of Fiscal 2022 Financial Results

 

Total revenues for the first half of fiscal year 2022 increased by 11.0% YoY to RMB628.8 million ($97.6 million) as the number of new subscribers continued to improve from the COVID-induced low base in the prior year period and the enlarged accumulated subscriber base. Revenues from processing fees and other services increased by 12.0% YoY to RMB364.9 million ($56.6 million) and revenues from storage fees increased by 9.7% YoY to RMB263.9 million ($41.0 million). Gross profit increased by 11.8% YoY to RMB534.8 million ($83.0 million). Operating income increased by 16.3% YoY to RMB317.0 million ($49.2 million). Non-GAAP operating income2 increased by 14.8% YoY to RMB341.3 million ($53.0 million). Net income attributable to the Company’s shareholders decreased by 0.7% to RMB262.2 million ($40.7 million). Basic and diluted earnings per ordinary share was RMB2.15 ($0.33). Net cash provided by operating activities improved by 20.1% YoY to RMB329.8 million ($51.2 million), partially due to a lower base in the prior year period.

 

 

 

 

Corporate Developments

 

·On March 2, 2021, the Board of Directors of the Company (the “Board”) received a non-binding proposal letter (the “Alternate Ocean Offer”) from Alternate Ocean Investment Company Limited (“Alternate Ocean”), pursuant to which Alternate Ocean, acting on behalf of certain funds and/or entities (the “Acquirer”) that it manages and/or advises, proposed to acquire all of the outstanding ordinary shares of the Company for $5.00 per ordinary share in cash, subject to certain conditions.

 

·On March 15, 2021, the Board announced it had formed a special committee of independent directors who are not affiliated with Alternate Ocean (the “Special Committee”) to evaluate the Alternate Ocean Offer. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu, Mr. Jack Chow and Mr. Jacky Cheng, each of whom currently serves as an independent director on the Board with Mr. Chen serving as the chair of the Special Committee.

 

·The Company cautions its shareholders and others considering trading its ordinary shares that no decisions have been made with respect to the Company’s response to the proposed transaction. The proposed transaction is still subject to various conditions, including but not limited to, completion of due diligence, parties entering into definitive agreement, and/or the Acquirer and the Company each obtaining the relevant regulatory and shareholders’ approval. There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that this or any other transaction will be approved or consummated.

 

Conference Call

 

The Company will host a conference call at 8:00 a.m. ET on Friday, November 26, 2021, to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company’s IR website at http://ir.globalcordbloodcorporation.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 14958969#.

 

 

 

1 During the three months and six months ended September 30, 2021, 19,066 and 38,739 new subscribers were recruited. During the three months and six months ended September 30, 2021, the Company determined that the recoverability of 1,169 and 2,084 private cord blood units was remote and therefore, the Company terminated their subscription services according to the subscription contracts. Out of these prior private cord blood units, 969 and 1,684 prior private cord blood units were being treated as if they were donated cord blood units and will be part of the Company’s non-current inventories. Hence, the net accumulated subscriber base was 938,092 as of September 30, 2021.

 

2 See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).

 

3 The reported operating income for the three months ended September 30, 2020 and 2021 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.3 million and RMB12.4 million ($1.9 million), respectively. The reported operating income for the six months ended September 30, 2020 and 2021 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB24.6 million and RMB24.3 million ($3.8 million), respectively.

 

 

 

 

Use of Non-GAAP Financial Measures

 

GAAP results for the three months and six months ended September 30, 2021 include non-cash items related to depreciation and amortization expenses. To supplement the Company’s unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company’s management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company’s historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

 

About Global Cord Blood Corporation

 

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at: http://www.globalcordbloodcorporation.com.

 

Safe Harbor Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

 

 

 

 

 

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the ongoing impact of COVID-19, including the partial lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC (including but not limited to cord blood license related regulations, Biosecurity laws, antitrust laws) and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, the non-binding proposal letter from Alternate Ocean and the potential transaction contemplated by such letter, and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

 

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ending September 30, 2021 were made at the noon buying rate of RMB6.4434 to $1.00 on September 30, 2021 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

 

For more information, please contact:

 

Global Cord Blood Corporation 

Investor Relations Department 

Tel: (+852) 3605-8180 

Email: [email protected]

 

ICR, Inc. 

William Zima 

Tel: (+86) 10-6583-7511 

U.S. Tel: (646) 405-5185 

Email: [email protected]

 

 

 

 

EXHIBIT 1

 

GLOBAL CORD BLOOD CORPORATION 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS 

As of March 31 and September 30, 2021

 

   March 31,   September 30, 
   2021   2021 
   RMB   RMB   US$ 
   (in thousands except share data) 
ASSETS               
Current assets               
Cash and cash equivalents   6,075,798    6,390,632    991,812 
Accounts receivable, less allowance for credit losses (March 31, 2021: RMB137,961; September 30, 2021: RMB150,060 (US$23,289))   130,298    144,667    22,452 
Inventories   44,257    33,821    5,250 
Prepaid expenses and other receivables   47,788    79,343    12,313 
Total current assets   6,298,141    6,648,463    1,031,827 
Property, plant and equipment, net   498,656    484,434    75,183 
Operating lease right-of-use assets   5,039    3,969    616 
Non-current deposits   344,752    343,529    53,315 
Non-current accounts receivable, less allowance for credit losses (March 31, 2021: RMB67,095; September 30, 2021: RMB62,544 (US$9,707))   217,208    241,377    37,461 
Inventories   91,446    93,261    14,474 
Intangible assets, net   88,202    85,892    13,330 
Investment in equity securities at fair value   117,911    108,974    16,912 
Other equity investment   189,129    189,129    29,352 
Deferred tax assets   55,845    59,230    9,192 
Total assets   7,906,329    8,258,258    1,281,662 
                
LIABILITIES               
Current liabilities               
Accounts payable   9,479    13,442    2,086 
Accrued expenses and other payables   136,448    153,872    23,880 
Operating lease liabilities   1,636    1,675    260 
Deferred revenue   449,359    451,022    69,998 
Income tax payable   29,547    30,767    4,775 
Total current liabilities   626,469    650,778    100,999 
Non-current deferred revenue   2,392,906    2,441,499    378,915 
Non-current operating lease liabilities   147    50    8 
Other non-current liabilities   482,224    495,826    76,951 
Deferred tax liabilities   16,132    16,701    2,592 
Total liabilities   3,517,878    3,604,854    559,465 
             
EQUITY               
Shareholders’ equity of Global Cord Blood Corporation               
Ordinary shares               
- US$0.0001 par value, 250,000,000 shares authorized, 121,687,974 and 121,551,075 shares issued and outstanding as of March 31 and September 30, 2021, respectively   83    83    13 
Additional paid-in capital   2,101,582    2,101,582    326,161 
Treasury stock, at cost (March 31 and September 30, 2021: 136,899 shares, respectively)   (2,815)   (2,815)   (437)
Accumulated other comprehensive losses   (103,179)   (105,354)   (16,351)
Retained earnings   2,386,187    2,648,344    411,016 
Total equity attributable to Global Cord Blood Corporation   4,381,858    4,641,840    720,402 
Non-controlling interests   6,593    11,564    1,795 
Total equity   4,388,451    4,653,404    722,197 
Total liabilities and equity   7,906,329    8,258,258    1,281,662 

 

 

 

 

EXHIBIT 2

 

GLOBAL CORD BLOOD CORPORATION 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 

For the Three Months and Six Months Ended September 30, 2020 and 2021

 

   Three months ended September 30,   Six months ended September 30, 
   2020   2021   2020   2021 
   RMB   RMB   US$   RMB   RMB   US$ 
   (in thousands except per share data) 
Revenues   285,607    313,670    48,681    566,520    628,844    97,595 
Cost of revenues   (44,698)   (46,209)   (7,172)   (88,161)   (94,050)   (14,596)
Gross profit   240,909    267,461    41,509    478,359    534,794    82,999 
Operating expenses                              
Research and development   (4,953)   (5,573)   (865)   (9,298)   (10,671)   (1,656)
Sales and marketing   (54,124)   (56,924)   (8,834)   (109,184)   (116,327)   (18,054)
General and administrative   (42,671)   (44,512)   (6,908)   (87,207)   (90,788)   (14,090)
Total operating expenses   (101,748)   (107,009)   (16,607)   (205,689)   (217,786)   (33,800)
Operating income   139,161    160,452    24,902    272,670    317,008    49,199 
Other income/(expenses), net                              
Interest income   8,810    7,989    1,240    15,577    16,179    2,511 
Foreign currency exchange gains/(losses)   66    (15)   (2)   108    131    20 
Change in fair value of equity securities   5,699    (12,616)   (1,958)   24,104    (7,015)   (1,089)
Dividend income   1,281    -    -    1,281    1,120    174 
Others   1,195    583    90    2,918    1,222    190 

Total other income/(expenses), net

   17,051    (4,059)   (630)   43,988    11,637    1,806 
Income before income tax   156,212    156,393    24,272    316,658    328,645    51,005 
Income tax expense   (22,890)   (28,251)   (4,384)   (48,911)   (61,517)   (9,547)
Net income   133,322    128,142    19,888    267,747    267,128    41,458 
Net income attributable to non-controlling interests   (1,888)   (2,406)   (373)   (3,804)   (4,971)   (772)
Net income attributable to Global Cord Blood Corporation’s Shareholders   131,434    125,736    19,515    263,943    262,157    40,686 
                               
Earnings per share:                              
Attributable to ordinary shares                              
- Basic   1.08    1.03    0.16    2.17    2.15    0.33 
- Diluted   1.08    1.03    0.16    2.17    2.15    0.33 
Other comprehensive losses, net of nil income taxes                              
- Foreign currency translation adjustments   (4,202)   (229)   (36)   (4,641)   (2,175)   (338)
Comprehensive income   129,120    127,913    19,852    263,106    264,953    41,120 
                               
Comprehensive income attributable to non-controlling interests   (1,888)   (2,406)   (373)   (3,804)   (4,971)   (772)
Comprehensive income attributable to Global Cord Blood Corporation’s shareholders   127,232    125,507    19,479    259,302    259,982    40,348 

 

 

 

 

EXHIBIT 3

 

GLOBAL CORD BLOOD CORPORATION 

RECONCILIATION OF NON-GAAP OPERATING INCOME 

For the Three Months and Six Months Ended September 30, 2020 and 2021

 

   Three months ended
September 30,		   Six months ended
September 30,		 
   2020   2021   2020   2021 
   RMB   RMB   US$   RMB   RMB   US$ 
   (in thousands) 
GAAP amount of operating income   139,161    160,452    24,902    272,670    317,008    49,199 
Depreciation and amortization expenses4   12,266    12,370    1,920    24,622    24,265    3,765 
Non-GAAP operating income   151,427    172,822    26,822    297,292    341,273    52,964 

 

 

 

4 Depreciation and amortization expenses relate to property, plant and equipment and intangible assets respectively.